Nateglinide acyl glucuronide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 577966

CAS#: 183996-85-2

Description: Nateglinide acyl glucuronide is a drug for the treatment of type 2 diabetes. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.


Chemical Structure

img
Nateglinide acyl glucuronide
CAS# 183996-85-2

Theoretical Analysis

MedKoo Cat#: 577966
Name: Nateglinide acyl glucuronide
CAS#: 183996-85-2
Chemical Formula: C25H35NO9
Exact Mass: 493.23
Molecular Weight: 493.550
Elemental Analysis: C, 60.84; H, 7.15; N, 2.84; O, 29.17

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Nateglinide acyl glucuronide

IUPAC/Chemical Name: (2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((2R)-2-((4-isopropylcyclohexanecarbonyl)amino)-3-phenyl-propanoyl)oxy-tetrahydropyran-2-carboxylic acid

InChi Key: YTIRWNSTJVSCRW-BBFBHBGISA-N

InChi Code: 1S/C25H35NO9/c1-13(2)15-8-10-16(11-9-15)22(30)26-17(12-14-6-4-3-5-7-14)24(33)35-25-20(29)18(27)19(28)21(34-25)23(31)32/h3-7,13,15-21,25,27-29H,8-12H2,1-2H3,(H,26,30)(H,31,32)/t15-,16-,17-,18+,19+,20-,21+,25+/m1/s1

SMILES Code: CC(C)[C@@H]1CC[C@H](CC1)C(=O)N[C@H](Cc2ccccc2)C(=O)O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 493.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Campbell IW. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. Int J Clin Pract. 2005 Oct;59(10):1218-28. Review. PubMed PMID: 16178991.

2: Phillips LS, Dunning BE. Nateglinide (Starlix): update on a new antidiabetic agent. Int J Clin Pract. 2003 Jul-Aug;57(6):535-41. Review. PubMed PMID: 12918894.

3: Tentolouris N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vasc Health Risk Manag. 2007;3(6):797-807. Review. PubMed PMID: 18200800; PubMed Central PMCID: PMC2350129.

4: Israel MK, Istvan E, Baron MA. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. Vasc Health Risk Manag. 2008;4(6):1167-78. Review. PubMed PMID: 19337530; PubMed Central PMCID: PMC2663444.

5: Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108. Review. PubMed PMID: 17253883.